drugset / Trial / NCT00005630
Vaccine Therapy and Sargramostim in Treating Patients With Non-small Cell Lung Cancer
Treatment
Summary
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Colony-stimulating factors such as sargramostim may increase the number of immune cells found in bone marrow or peripheral blood. PURPOSE: Phase I trial to study the effectiveness of vaccine therapy and sargramostim in treating patients who have non-small cell lung cancer.
Timeline
- Start
- 1999-07
- Primary completion
- 2002-05
- Completion
- 2002-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ras peptide cancer vaccine | Vaccine | — | Other |
| Subject | sargramostim | Protein / enzyme biologic | — | Other |